[Funding News] Maiva Pharma Secures INR 1000 Cr From Morgan Stanley Private Equity, InvAscent

Maiva Pharma, an injectables Contract Development and Manufacturing Organisation (CDMO), has secured Rs 1,000 crores in both primary and secondary financing from a fund managed by Morgan Stanley Private Equity Asia and India Life Sciences Fund - IV (InvAscent).

After the initial investment, the combined finance of the India Life Sciences Fund and Morgan Stanley PE Asia would exceed 60%. The funds are investing nearly equally, as reported by The Economic Times.

Read also - [Funding News] Go DESi Secures Rs 41 Cr From Avishkaar Capital, Others

The organisation intends to use the capital raised to build an additional manufacturing plant close to Hosur, Karnataka, that will produce sterility dosage.

Maiva has established a solid reputation for quality and dependability in the market by adhering to strict compliance and quality standards. Both aseptically filled and terminally sterilised items can be produced at this facility.

With two decades of experience in Sterile Manufacturing, Maiva have capabilities to perform end to end integrated pharmaceutical development and manufacturing.

About Maiva Pharma

Maiva Pharma Private Limited, formerly known as Global Pharmatech, started operations in 1996, as a manufacturer of high quality liquid sterile formulations in small volume glass vials and ampoules, and large volume glass bottles.

Want to go deeper into the world of startups and entrepreneurship? Check out these categories on VIESTORIES:

Startup Success Stories: Discover inspiring tales of startups overcoming challenges and achieving success.

Funding Startup News: Stay updated with the latest news and trends in startup funding and investment.

Startup Insights: Dive into in-depth analyses of various industries and market trends to make informed business decisions.

Advertisment